Table 2 Grade ≥ 3 adverse events and dose discontinuation rate in overall and subgroup analysis.

		No. of studies	No. of patients	Arm	Patients	Adverse events (%)	Pooled OR (95% CI)	p-value	I² (%)
Neutropenia^2,3,4,5,6,10	Overall	5	1,541	nab, nab + bev sb, sb + bev	767 774	356 (46.4) 362 (46.8)	0.46 (0.12–1.79)	0.26	96
Neutropenia^2,3,4,5,6,10	Subgroup	4	1,006	nab sb	504 502	222(44.0) 312(62.2)	0.26 (0.09–0.78)	0.02^†	90
Leukopenia^2,3,6,10	Overall	4	1,393	nab, nab + bev sb, sb + bev	693 700	143 (20.6) 153 (21.9)	0.77 (0.25–2.44)	0.66	92
Leukopenia^2,3,6,10	Subgroup	3	858	nab sb	430 428	97(22.6) 132(30.8)	0.51 (0.16–1.59)	0.24	87
Sensory neuropathy^2,3,4,5,6,10	Overall	5	1,541	nab, nab + bev sb, sb + bev	767 774	139 (18.1) 73 (9.4)	2.44 (1.42–4.20)	0.001^†	53
Sensory neuropathy^2,3,4,5,6,10	Subgroup	4	1,006	nab sb	504 502	69(13.7) 25(5.0)	2.90 (1.45–5.79)	0.003^†	48
Fatigue^2,4,5,6,10	Overall	4	1,331	nab, nab + bev sb, sb + bev	663 668	61 (9.2) 44 (6.6)	1.34 (0.35–5.22)	0.67	79
Fatigue^2,4,5,6,10	Subgroup	3	796	nab sb	400 396	18(4.5) 17(4.3)	1.25 (0.10–5.16)	0.86	85
Dose discontinuation rate^3,4,5,6,10	Overall	4	1,093	nab, nab + bev sb, sb + bev	541 552	112 (20.7) 85 (15.4)	1.23 (0.68–2.25)	0.49	62
Dose discontinuation rate^3,4,5,6,10	Subgroup	3	558	nab sb	278 280	42(15.1) 54(19.3)	0.89 (0.55–1.43)	0.64	0

Abbreviations: nab, nanoparticle albumin-bound paclitaxel; sb, solvent-based taxanes; bev, bevacizumab; OR, odds ratio; CI, confidence interval.
^†Statistically significant when p < 0.05.
Overall includes all studies with adverse events data.
Subgroup includes therapy with nab-paclitaxel vs solvent-based taxanes (sb-paclitaxel and docetaxel).

Quick links

Search